HIV-1 superinfection despite broad cd8+ T-cell responses containing replication of the primary virus

Nature

Volumn 420, Issue 6914, 2002, Pages 434-439

  Altfeld, Marcus ^a   Allen, Todd M ^a   Yu, Xu G ^a   Johnston, Mary N ^a   Agrawal, Deepak ^a   Korber, Bette T ^b   Montefiori, David C ^c   O'Connor, David H ^d   Davis, Ben T ^a   Lee, Paul K ^a   Maier, Erica L ^a   Harlow, Jason ^a   Goulder, Philip J R ^a,e   Brander, Christian ^a   Rosenberg, Eric S ^a   Walker, Bruce D ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b LOS ALAMOS NATIONAL LABORATORY   (United States)

^c DUKE UNIVERSITY MEDICAL CENTER   (United States)

^d UNIVERSITY OF WISCONSIN   (United States)

^e UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

HEALTH; IMMUNOLOGY; PROTEINS; VACCINES; VIRUSES;

EPITOPES;

CELLS;

ANTIRETROVIRUS AGENT; STI 546D; UNCLASSIFIED DRUG;

HUMAN IMMUNODEFICIENCY VIRUS;

ARTICLE; CASE REPORT; DISEASE COURSE; HELPER CELL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; LYMPHOCYTE COUNT; MOLECULAR RECOGNITION; PRIORITY JOURNAL; T LYMPHOCYTE; TREATMENT OUTCOME; VIREMIA; VIRUS LOAD; VIRUS PATHOGENESIS; VIRUS REPLICATION;

HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; RNA VIRUSES;

EID: 18744363385     PISSN: 00280836     EISSN: None     Source Type: Journal    
DOI: 10.1038/nature01200     Document Type: Article

References (27)

1. Lisziewicz, J. et al. Control of HIV despited the discontinuation of antiretroviral therapy. N. Engl. J. Med. 340, 1683-1684 (1999).
2. Ortiz, G. M. et al. HIV-1-specific immune responses in subjects who temporarily contain virus replication after discontinuation of highly active antiretroviral therapy. J. Clin. Invest. 104, R13-R18 (1999).
3. Rosenberg, E. S. et al. Immune control of HIV-1 after early treatment of acute infection. Nature 407, 523-526 (2000).
4. + cytotoxic T-lymphocyte activity associated with control of viremia in primary human immunodeficiency virus type 1 infection. J. Virol. 68, 6103-6110 (1994).
5. + T cell depletion in simian immunodeficiency virus-infected macaques. J. Exp. Med. 189, 991-998 (1999).
6. Koup, R. A. et al. Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome. J. Virol. 68, 4650-4655 (1994).
7. + lymphocytes. Science 283, 857-860 (1999).
8. Allen, T. M. et al. Tat-specific cytotoxic T lymphocytes select for SIV escape variants during resolution of primary viraemia. Nature 407, 386-390 (2000).
9. Barouch, D. H. et al. Control of viremia and prevention of clinical AIDS in rhesus monkeys by cytokine-augmented DNA vaccination. Science 290, 486-492 (2000).
10. Amara, R. R. et al. Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/ MVA vaccine. Science 292, 69-74 (2001).
11. Shiver, J. W. et al. Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity. Nature 415, 331-335 (2002).
12. Hanke, T. et al. Effective induction of simian immunodeficiency virus-specific cytotoxcic T lymphocytes in macaques by using a multiepitope gene and DNA prime-modified vaccinia virus Ankara boost vaccination regimen. J. Virol. 73, 7524-7532 (1999).
13. Allen, T. M. et al. Tat-vaccinated macaques do not control simian immunodeficiency virus SIV mac239 replication. J. Virol. 76, 4108-4112 (2002).
14. Feinberg, M. B. & Moore, J. P. AIDS vaccine models: Challenging challenge viruses. Nature Med. 8, 207-210 (2002).
15. Malhotra, U. et al. Effect of combination antiretroviral therapy on T-cell immunity in acute human immunodeficiency virus type 1 infection. J. Infect. Dis. 181, 121-131 (2000).
16. + T lymphocytes. Proc Natl. Acad. Sci. USA 97, 3382-3387 (2000).
17. + T cells. Nature 417, 95-98 (2002).
18. Barouch, D. H. et al. Eventual AIDS vaccine failure in a rhesus monkey by viral escape from cytotoxic T lymphocytes. Nature 415, 335-339 (2002).
19. + T-cell responses following acute HIV-1 infection. J. Virol. 76, 8690-8701 (2002).
20. Montefiori, D. C., Hill, T. S., Vo, H. T., Walker, B. D. & Rosenberg, E. S. Neutralizing antibodies associated with viremia control in a subset of individuals after treatment of acute human immunodeficiency virus type 1 infection. J. Virol. 75, 10200-10207 (2001).
21. Altfeld, M. A. et al. Identification of dominant optimal HLA-B60- and HLA-B61-restricted cytotoxic T-lymphocyte (CTL) epitopes: Rapid characterization of CTL responses by enzyme-linked immunospot assay. J. Virol. 74, 8541-8549 (2000).
22. Del Val, M., Schlicht, H. J., Ruppert, T., Reddehase, M. J. & Koszinowski, U. H. Efficient processing of an antigenic sequence for presentation by MHC class I molecules depends on its neighbouring residues in the protein. Cell 66, 1145-1153 (1991).
23. Ramos, A. et al. Intersubtype human immunodeficiency virus type 1 superinfection following seroconversion to primary infection in two injection drug users. J. Virol. 76, 7444-7452 (2002).
24. Jost, S. et al. A patient with HIV-1 superinfection. N. Engl. J. Med. 347, 731-736 (2002).
25. McCutchan, F. E. Understanding the genetic diversity of HIV-1. AIDS 14, S31-S44 (2000).
26. Brander, C., Goulder, P. J. R., et al. HIV Molecular Database (ed. Korber, B. T. M.) 11-120 (Los Alamos National Laboratory, Los Alamos, NM, 1999).
27. Felsenstein, J. PHYLIP - Phylogeny Inference Package Version 3.5c, (Dept. Genetics, Univ. Washington, Seattle, 1989).